Anti-ACM4/ CHRM4/ HM4 monoclonal antibody

Anti-ACM4/ CHRM4/ HM4 antibody for FACS & in-vivo assay

Target products collectionGo to CHRM4/CHRM4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T20709-Ab-1/ GM-Tg-hg-T20709-Ab-2Anti-Human CHRM4 monoclonal antibodyHuman
GM-Tg-rg-T20709-Ab-1/ GM-Tg-rg-T20709-Ab-2Anti-Rat CHRM4 monoclonal antibodyRat
GM-Tg-mg-T20709-Ab-1/ GM-Tg-mg-T20709-Ab-2Anti-Mouse CHRM4 monoclonal antibodyMouse
GM-Tg-cynog-T20709-Ab-1/ GM-Tg-cynog-T20709-Ab-2Anti-Cynomolgus/ Rhesus macaque CHRM4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T20709-Ab-1/ GM-Tg-felg-T20709-Ab-2Anti-Feline CHRM4 monoclonal antibodyFeline
GM-Tg-cang-T20709-Ab-1/ GM-Tg-cang-T20709-Ab-2Anti-Canine CHRM4 monoclonal antibodyCanine
GM-Tg-bovg-T20709-Ab-1/ GM-Tg-bovg-T20709-Ab-2Anti-Bovine CHRM4 monoclonal antibodyBovine
GM-Tg-equg-T20709-Ab-1/ GM-Tg-equg-T20709-Ab-2Anti-Equine CHRM4 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T20709-Ab-1/ GM-Tg-hg-T20709-Ab-2; GM-Tg-rg-T20709-Ab-1/ GM-Tg-rg-T20709-Ab-2;
GM-Tg-mg-T20709-Ab-1/ GM-Tg-mg-T20709-Ab-2; GM-Tg-cynog-T20709-Ab-1/ GM-Tg-cynog-T20709-Ab-2;
GM-Tg-felg-T20709-Ab-1/ GM-Tg-felg-T20709-Ab-2; GM-Tg-cang-T20709-Ab-1/ GM-Tg-cang-T20709-Ab-2;
GM-Tg-bovg-T20709-Ab-1/ GM-Tg-bovg-T20709-Ab-2; GM-Tg-equg-T20709-Ab-1/ GM-Tg-equg-T20709-Ab-2
Products NameAnti-CHRM4 monoclonal antibody
Formatmab
Target NameCHRM4
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CHRM4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species ACM4/ CHRM4/ HM4 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-T20709
    Target NameCHRM4
    Gene ID1132,12672,25111,574195,611314,101088360,512928,102147631
    Gene Symbol and SynonymsAChR M4,Chrm-4,CHRM4,HM4,M3R,M4,M4R,mm4 mAChR
    Uniprot AccessionP08173,P08485,P41986
    Uniprot Entry NameACM4_HUMAN,ACM4_RAT,ACM4_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000180720
    Target ClassificationGPCR

    The target: CHRM4, gene name: CHRM4, also named as HM4, M4R. The muscarinic cholinergic receptors belong to a larger family of G protein-coupled receptors. The functional diversity of these receptors is defined by the binding of acetylcholine and includes cellular responses such as adenylate cyclase inhibition, phosphoinositide degeneration, and potassium channel mediation. Muscarinic receptors influence many effects of acetylcholine in the central and peripheral nervous system. The clinical implications of this receptor are unknown; however, mouse studies link its function to adenylyl cyclase inhibition. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.